Why Is VIKING THERAPEUTICS (VKTX) Stock Moving Today?

Why VKTX stock is moving today

VKTX stock is moving lower today amid mixed signals from the market and recent insider activity. The stock has declined 66% from its 52-week high of $43.15 and is trading near the lower end of its range at $22.96. Recent analyst activity has included both a lowered price target from JPMorgan and a raised target from Canaccord Genuity, while insider sales by top executives have added to investor uncertainty.

What Happened

Viking Therapeutics is facing a period of volatility as the stock continues to trade below its peak. The company reported Q2 earnings of $(1.10) per share, which beat the estimate of $(1.25), but remains unprofitable with a trailing twelve-month EPS of -4.67. JPMorgan has maintained an Overweight rating on the stock but reduced its price target to $65, while Canaccord Genuity has kept a Buy rating and raised its target to $114. These diverging views reflect ongoing uncertainty about the company’s clinical trial outcomes and the potential for its lead drug candidate to deliver on early promise.

Insider transactions have also drawn attention. On July 29, 2026, Viking’s COO, CEO, and CFO each sold shares, marking the third instance of insider sales in the last 90 days. These sales totaled $6.3 million and occurred without any corresponding buy activity, signaling a lack of confidence from company leadership.

What The Data Shows

The stock has traded in a 52-week range of $22.96 to $43.15 and has a market capitalization of $3.8 billion. With a beta of 0.68, it is less volatile than the broader market. The 30-day average sentiment score is 50 out of 100, while the seven-day score has dropped to 41, indicating a recent deterioration in market sentiment. This aligns with the downward pressure on the stock.

What To Watch

Investors should monitor Viking Therapeutics’ clinical trial data and any further analyst commentary. The stock remains speculative, and its performance will likely depend on the strength of its pipeline and the market’s reaction to upcoming developments.